JP2024508823A - 治療目的のための新規のウイルス粒子 - Google Patents

治療目的のための新規のウイルス粒子 Download PDF

Info

Publication number
JP2024508823A
JP2024508823A JP2023551984A JP2023551984A JP2024508823A JP 2024508823 A JP2024508823 A JP 2024508823A JP 2023551984 A JP2023551984 A JP 2023551984A JP 2023551984 A JP2023551984 A JP 2023551984A JP 2024508823 A JP2024508823 A JP 2024508823A
Authority
JP
Japan
Prior art keywords
segment
lcmv
seq
virus
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508823A5 (enExample
Inventor
イェルク フォルマー
マルクス コストカ
フィリップ ラング
ハイフェン シュー
Original Assignee
アバロス セラピューティクス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アバロス セラピューティクス ゲーエムベーハー filed Critical アバロス セラピューティクス ゲーエムベーハー
Publication of JP2024508823A publication Critical patent/JP2024508823A/ja
Publication of JP2024508823A5 publication Critical patent/JP2024508823A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2023551984A 2021-02-26 2022-02-25 治療目的のための新規のウイルス粒子 Pending JP2024508823A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21159746 2021-02-26
EP21159746.3 2021-02-26
PCT/EP2022/054766 WO2022180203A1 (en) 2021-02-26 2022-02-25 New virus particles for therapeutic purposes

Publications (2)

Publication Number Publication Date
JP2024508823A true JP2024508823A (ja) 2024-02-28
JP2024508823A5 JP2024508823A5 (enExample) 2025-02-25

Family

ID=74844711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551984A Pending JP2024508823A (ja) 2021-02-26 2022-02-25 治療目的のための新規のウイルス粒子

Country Status (11)

Country Link
US (1) US20220273741A1 (enExample)
EP (1) EP4297763A1 (enExample)
JP (1) JP2024508823A (enExample)
KR (1) KR20230153411A (enExample)
CN (1) CN117241812A (enExample)
AU (1) AU2022226407A1 (enExample)
CA (1) CA3208055A1 (enExample)
CL (1) CL2023002508A1 (enExample)
IL (1) IL305349A (enExample)
MX (1) MX2023009650A (enExample)
WO (1) WO2022180203A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025046106A1 (en) 2023-08-31 2025-03-06 Abalos Therapeutics Gmbh Virus particles with improved entry into tumor cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018533604A (ja) * 2015-11-12 2018-11-15 ホオキパ バイオテック エージー 癌ワクチンとしてのアレナウイルス粒子
WO2020053324A1 (en) * 2018-09-12 2020-03-19 Abalos Therapeutics Gmbh Method for producing an antitumoral arenavirus as well as arenavirus mutants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461B4 (de) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018533604A (ja) * 2015-11-12 2018-11-15 ホオキパ バイオテック エージー 癌ワクチンとしてのアレナウイルス粒子
WO2020053324A1 (en) * 2018-09-12 2020-03-19 Abalos Therapeutics Gmbh Method for producing an antitumoral arenavirus as well as arenavirus mutants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. EXP. MED., vol. 172, JPN6026006527, 1990, pages 1043 - 1048, ISSN: 0005799550 *
JOURNAL OF VIROLOGY, vol. 55, no. 3, JPN6026006526, 1985, pages 704 - 709, ISSN: 0005799549 *
PLOS PATHOGENES, vol. Vol.11, No.11, e1005276, JPN6026006525, 2015, pages 1 - 25, ISSN: 0005799548 *
PNAS, 2010,, vol. 107, no. 50, JPN6026006528, 2010, pages 21641 - 21646, ISSN: 0005799551 *

Also Published As

Publication number Publication date
WO2022180203A1 (en) 2022-09-01
EP4297763A1 (en) 2024-01-03
US20220273741A1 (en) 2022-09-01
CA3208055A1 (en) 2022-09-01
MX2023009650A (es) 2023-08-24
CL2023002508A1 (es) 2024-01-26
AU2022226407A9 (en) 2024-01-25
CN117241812A (zh) 2023-12-15
IL305349A (en) 2023-10-01
KR20230153411A (ko) 2023-11-06
AU2022226407A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US20240100106A1 (en) Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers
CN110305198B (zh) 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
US20220213161A1 (en) Modified interleukin 12 and use thereof in preparing drugs for treating tumours
JP5797638B2 (ja) ニューロンの発生、再生および保護
WO2010080909A1 (en) Compositions and methods of use of an oncolytic vesicular stomatitis virus
JP7132339B2 (ja) 腫瘍を治療するための仮性狂犬病ウイルス
Kleinlützum et al. Enhancing the oncolytic activity of CD133-targeted measles virus: receptor extension or chimerism with vesicular stomatitis virus are most effective
KR102768669B1 (ko) 종양 치료용 콕삭키바이러스 b
Hatami et al. Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype
US20220273741A1 (en) New virus particles for therapeutic purposes
WO2019183802A1 (zh) 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
JP2020537534A (ja) 腫瘍を治療するためのエコーウイルス
WO2011056993A1 (en) Compositions and methods for treating cancer with attenuated oncolytic viruses
JP7227654B2 (ja) 固形癌及び微生物感染を治療するための方法及び組成物
US20250195634A1 (en) Novel usage of oncolytic gene-modified measles virus
JP7857683B2 (ja) 腫瘍溶解性ウイルス及びその使用
WO2025119999A1 (en) Extracellular vesicle based vaccine platform
Hanauer Increasing oncoselectivity of virotherapy: Receptor targeted viruses against CD30-positive malignancies
CN118256561A (zh) 靶向双激酶aurka/cdk7的疫苗在治疗实体瘤中的应用
Pandey Expression of Bovine Alpha Interferon and Evaluation of Its Biological Activity in Vitro

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260512